On the evening of November 20, the official WeChat public account of the Shanghai Discipline Inspection Commission "Integrity Shanghai" released news that Zhou Jun, president of Shanghai Industrial (Group) Co., Ltd., was suspected of serious disciplinary violations.Supervision and investigation.
On the same day, Shanghai Pharmaceutical (601607.SH) also issued an announcement. On November 18, the company's board of directors received a written resignation report from Zhou Jun. Due to personal affairs, Zhou Jun could not invest enough time to perform the company's position.The chairman, non -executive director, convener of the strategic committee of the board of directors, and members of the Strategic Committee of the Directors have come into effect from the date of delivery from the board of directors of the company.In addition, Shanghai Industrial Holdings (00363.HK) and Shanghai Industrial Environment (00807.HK) also announced that Zhou Jun applied to resign all his positions.
The above -mentioned company stated in the announcement that Zhou Jun has confirmed that there is no disagreement with the board of directors, and there is no such thing as a resignation.The above matters have no significant impact on the company's daily operations.
Public information shows that Zhou Jun, a bachelor's degree in literature from Nanjing University, a master's degree in international financial majors at Fudan University, Ph.D.Zhou Jun has nearly 30 years of professional work experience in securities, acquisitions, financial investment, real estate, project planning and corporate management.
In April 1996, Zhou Jun joined the Shanghai Industrial Group. He was the executive director of Shanghai Industrial City Development Group Co., Ltd. (00563.HK) and Zhejiang, Shanghai -Hangzhou -Governor Highway Co., Ltd. (00576.HK) independent non -executive director, Vice President of Shanghai Industrial (Group) Co., Ltd., general manager of investment planning department, deputy general manager of Shanghai Real Estate Group (Shanghai) Co., Ltd. and Shanghai United Industrial Co., Ltd., CEO of Deputy Administration of Shanghai Industrial Holding Co., Ltd., Shanghai Xinghe Digital InvestmentDirector of the director of the company.
From October 20, 2016, Zhou Jun began to serve as chairman of Shanghai Medicine.According to the Shanghai Pharmaceutical Announcement, on June 29 this year, at the first meeting of the eighth board of directors of the company, Zhou Jun was re -elected as chairman of the company and should end his term in 2026.
Nantu · Bay Financial Reporter Shanghai Medicine is a member of the Shanghai Industrial Group.In terms of performance, in the first three quarters of this year, Shanghai's pharmaceutical revenue was 197.508 billion yuan, an increase of 13.11%year -on -year; the net profit attributable to mothers was 3.797 billion yuan, a year -on -year decrease of 21.13%.Among them, in the third quarter, operating income was 64.916 billion yuan, an increase of 3.2%year -on -year; net profit attributable to mother was 1.187 billion yuan, an increase of 6.14%year -on -year.As of the close of November 20, Shanghai Pharmaceutical's stock price closed at 17.92 yuan/share, with a total market value of 66.36 billion yuan.
In addition, Zhou Jun has also served as representatives of the 16th People's Congress of Shanghai, President of the Shanghai Medical Industry Association, the chairman of the Shanghai Environmental Protection Industry Association, the president of the Shanghai Youth Entrepreneurs Association, and Shanghai immunotherapyDirector of Innovation Research Institute.
Since the beginning of this year, Shanghai's pharmaceutical industry has set off a storm of anti -corruption, and many high -level high -level companies have been investigated.On September 2nd, the Shanghai Municipal Commission for Discipline Inspection issued news that four cadres of Shanghai Pharmaceuticals and subordinate companies received disciplinary review and supervision investigations, including Pan Deqing, former vice president of Shanghai Pharmaceutical Group Co., Ltd.Li Ping, general manager of Shanghai Shangke Pharmaceutical Co., Ltd., Chen Binhua, former general manager of Shanghai Shang Pharmaceutical Pharmaceutical Co., Ltd., and Huang Zhenhui, former deputy general manager of Shanghai Shang Pharmaceutical Pharmaceutical Co., Ltd.
Anti -corruption in the medical field that has continued to deepen the recent deepening, at the 2023 Jinan Biomedical and Big Health Industry Seminar held on August 10, Zhou Jun said that Shanghai Medicine will cooperate fully and resolutely implement it."This industry wants to earn huge profits. Its public welfare, importance, and special nature determines that‘ serving the people and serving the country ’is always the industry’ s highest value. ”
Writing: Peng Leyi, a reporter from the Nandu Bay Publicity, Qiu Mushan
